Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Net Revenue Increased 43% from Second Quarter 2022 Largest Quarter-over-Quarter Increase in Net Revenue Achieved by Agile   Non-Retail Channel Twirla Cycles Grew 361% from Second Quarter 2022 Company Expects Business Plan Can Deliver Additional Growth in the Fourth Quarter of 2022 and in 2023...
Toggle Summary Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022
Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report third quarter 2022 financial results after the market close on Monday, November 7, 2022....
Toggle Summary Agile Therapeutics Announces Reorganization of Leadership Team
Appointment of Amy Welsh to Chief Commercial Officer Prioritizes Commercial Growth Company Streamlines Leadership Team to Align with Plan to Grow Twirla ® James Tursi, M.D. Resigns from Board of Directors PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc....
Toggle Summary Agile Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
PRINCETON, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Chairman and Chief Executive Officer Al Altomari and Vice President of Marketing Amy Welsh will present at the H.C....
Toggle Summary Agile Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Second Consecutive Quarter of Increase in Twirla Demand and Decrease in Company Operating Expenses Cash on Hand Expected to Fund Operations Through 2022 Company Announces Twirla ® Product Supply Agreement with Nurx Management to Host Conference Call Today, Thursday, August 11, 2022 at 4:30 p.m....
Toggle Summary Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022
Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2022 financial results after the market close on Thursday, August 11, 2022....
Toggle Summary Agile Therapeutics Updates Second Quarter 2022 Guidance
Twirla® Demand Guidance (Total Cycles) Expected to be at Midpoint of Guided Range Operating Expenses (OPEX) Expected to be Below Guided Range PRINCETON, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that it has updated its...
Toggle Summary Agile Therapeutics to Participate in Maxim Group’s Upcoming Women’s Health Panel
PRINCETON, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be participating in a virtual panel discussion presented by Maxim Group LLC and hosted by M-Vest....
Toggle Summary Agile Therapeutics Announces Closing of $24 Million Upsized Public Offering
PRINCETON, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the closing of its previously announced upsized public offering of an aggregate of 26,666,666 shares of its common stock...
Toggle Summary Agile Therapeutics Announces Pricing of $24 Million Upsized Public Offering
PRINCETON, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the pricing of its upsized public offering of an aggregate of 26,666,666 shares of its common stock (or pre-funded...
Shadow